Compare MLM & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLM | ZTS |
|---|---|---|
| Founded | 1993 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 31.2B |
| IPO Year | 1996 | 2012 |
| Metric | MLM | ZTS |
|---|---|---|
| Price | $565.61 | $81.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $689.36 | $154.18 |
| AVG Volume (30 Days) | 510.5K | ★ 6.8M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | 0.54% | ★ 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | ★ 25.06 | 1.42 |
| Revenue | $6,150,000,000.00 | ★ $9,467,000,000.00 |
| Revenue This Year | $13.76 | $5.63 |
| Revenue Next Year | $7.98 | $4.77 |
| P/E Ratio | ★ $22.06 | $57.25 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $525.38 | $73.82 |
| 52 Week High | $710.97 | $167.38 |
| Indicator | MLM | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 41.22 |
| Support Level | $554.72 | $74.35 |
| Resistance Level | $629.63 | $82.34 |
| Average True Range (ATR) | 16.05 | 2.21 |
| MACD | 1.02 | 1.81 |
| Stochastic Oscillator | 57.96 | 83.23 |
Martin Marietta Materials is one of the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). In 2024, Martin Marietta sold 191 million tons of aggregates. Martin Marietta's most important markets include Texas, North Carolina, Colorado, California, and Georgia, accounting for most of its sales. The company also uses its aggregates in its asphalt and ready-mixed concrete businesses. Martin's magnesia specialties business produces magnesia-based chemical products and dolomitic lime.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.